



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

23 January 2020

G MEDICAL APPROVED TO TRADE ON US OTCQB MARKET

- **G Medical now trading on OTC market in the USA under code GMMVF**
- **Provides access to individual and institutional investors in one of the world's largest capital markets**
- **Product suite continues to gain traction in USA – multiple growth opportunities pending**

Mobile and e-Health company **G Medical Innovations (ASX: GMV)** ("**G Medical**" or the "**Company**") is pleased to advise that its application to join the OTCQB ("OTC") market in the United States of America has been accepted and the Company's shares are now tradeable under the code GMMVF.

The Company's primary listing will continue to be the Australian Securities Exchange ("ASX"), with shares now tradeable on the OTCQB market (www.otcmarkets.com). The OTCQB is a US based financial market operated by the OTC Markets Group in New York. The OTCQB quality standards provide a strong platform of transparency and regulation to improve the trading experience for US investors.

The OTC market provides G Medical with access to individual and institutional American investors, and an entry point into one of the world's largest capital markets, at a nominal cost with no additional compliance requirements. Further, the listing is non-dilutive for shareholders, as no capital is required to be raised and no additional shares will be issued on the OTCQB market.

Now that G Medical has the required financial flexibility to rapidly scale, the Company will dedicate resources to increasing its operational and investor footprint in the US. GMV's product suite is continuing to gain traction with medical organisations and healthcare professionals and a number of opportunities are developing. Board and management look forward to updating shareholders as these progress.

CEO and Executive Director Dr Yacov Geva said: "Receiving the approval to trade on the OTCQB market provides G Medical with access to the world's largest investment market at minimal expense and no additional compliance requirements.

"The Company's product suite is continuing to gain traction with medical organisations and healthcare professionals in the United States and this listing will allow GMV to broaden its footprint in the country.

"An active shareholder engagement program is planned in the USA to ensure our investment attractions and growth prospects are highlighted amongst new investors."

Authorised for release by Dr Yacov Geva, CEO and Managing Director of the Company.

Ends

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About OTCQB:

The OTCQB is a US based financial market operated by OTC Markets Group in New York and it is the second highest tier of the US OTC markets. The OTCQB quality standards provide a strong platform of transparency, regulation and technology to improve the information and trading experience for US based investors.

Existing ASX listed companies on the OTC include; Alumina Limited, Fortescue Metals Group, Clean TeQ, Starpharma, Bionomics, Ellex Medical Lasers, Deep Yellow, Energy World Corp, AusCann Group and Elixinol Global. In addition to multi-nationals Roche (\$210bn market cap), Deutsche Telekom (\$78bn), BASF (\$75bn), BNP Paribas (\$65bn), AXA (\$64bn), Publicis Groupe (\$56bn), Imperial Brands (\$55bn), Heineken (\$50bn), Danone (\$48bn), Adidas (\$44bn), Sky PLC (\$38bn) and Anglo American (\$32bn).

Further information can be found at www.otcmarkets.com

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.